Briton Pharma’s anti-COVID drug Molviton to hit Indian market next week
Each pack will have 40 capsules as general recommended dosage is 800 mg twice/day for five days
Brinton Pharmaceutical yesterday said that it will launch Molnupiravir with brand name ‘Molviton.’
“Our brand Molviton would be available at all leading pharmacies and COVID treatment centres across the country by next week,” a statement quoted Rahulkumar Darda, Chairman and Managing Director, Brinton Pharmaceuticals, as saying.
He was further quoted as saying, “Our brand Molviton will be useful and effective in the treatment of mild-to-moderate cases of COVID-19. The drug will be available in 200 mg capsule form as a patient compliance.”
Each pack will have 40 capsules as general recommended dosage is 800 mg twice/day for five days. Going forward, the company is also working on 400 mg and 800 mg capsules. It will be available at all leading pharmacies and COVID treatment centres across the country, according to the statement.
- Advertisement -